-+ 0.00%
-+ 0.00%
-+ 0.00%

Northstrive Biosciences A Subsidiary of PMGC Holdings Enters Into A Development And License Agreement With Yuva Biosciences To Discover And Develop Novel Pharmaceutical Treatments For Obesity, Type 2 Diabetes and Other Cardiometabolic Conditions

Benzinga·04/10/2025 12:03:13
Listen to the news
  • Northstrive Biosciences and Yuva Biosciences' collaboration will leverage MitoNova™, YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.
  • Northstrive and Yuva Biosciences will compile a library of small molecule candidates that promote mitochondrial health and target the root cause of aging at the cellular level.

NEWPORT BEACH, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive" or "Northstrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC," "we," or "our"), announced today that it has entered into a Development and License Agreement ("Agreement") with Yuva Biosciences, Inc. ("YuvaBio" or "Yuva Biosciences") to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions using YuvaBio's proprietary, mitochondrial science-focused platform MitoNova, powered by artificial intelligence ("AI").

The Agreement provides for the parties' collaboration on an AI Development Program ("Program" or "AI Development Program"). As part of this Program, YuvaBio will develop mitochondrial science related technology for Northstrive and identify drug candidates with the potential to improve mitochondrial health and cardiometabolic function. YuvaBio will then test its computational findings for biological activity on custom assays. YuvaBio will also grant Northstrive an exclusive, worldwide license to this developed technology to derive therapeutic products for cardiac diseases and obesity. Through this collaboration, the parties aim to integrate new methodologies into mitochondrial biology and discover outputs to expand Northstrive's cardiometabolic disease pipeline.